Meditrina, Inc., a San Jose, CA-based women’s healthcare company and the developer of the Aveta™ System for the treatment of various intrauterine pathologies such as polyps and fibroids, completed a $13m equity financing.
The round was led by ShangBay Capital LLC and Aethan Capital, Inc. Concurrent with the financing, William Dai, Founding Managing Partner of ShangBay Capital, will join the Meditrina Board of Directors.
The company intends to use the proceeds to launch the US commercialization of the Aveta™ System that received U.S. Food and Drug Administration (FDA) 510(k) clearance in May 2019.
Led by Csaba Truckai, President and CEO, Meditrina is advancing the Aveta™ System, which is intended for hysteroscopic tissue chip resection under continuous flow conditions using a proprietary expandable working channel hysteroscope, combined with a fluid management and resection system, where the physician is able to control all parameters of the procedure and view it on a single monitor.
FinSMEs
02/10/2019